Drug delivery strategies for Alzheimer's disease treatment

Expert Opinion on Drug Delivery

Volumn 8, Issue 5, 2011, Pages 581-603

  Di Stefano, Antonio ^a   Iannitelli, Antonio ^a   Laserra, Sara ^a   Sozio, Piera ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Alzheimers disease; drug delivery devices; drug delivery systems; pharmaceutical formulations; therapeutic strategies

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALPHA SECRETASE; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTRADIOL; ESTROGEN; EUDRAGIT; GALANTAMINE; GAMMA SECRETASE; MEMANTINE; METAL CHELATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINE PATCH; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENSERINE; PHYSOSTIGMINE; POLYPHENOL; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ATTENTION; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; IONTOPHORESIS; LIVER TOXICITY; MEMORY; NANOTECHNOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN CLEAVAGE; RECOMMENDED DRUG DOSE; REVIEW; SKIN IRRITATION; SLEEP DISORDER; TABLET DISINTEGRATION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET HARDNESS; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS;

EID: 79955077392     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.561311     Document Type: Review

References (171)

1. Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimers disease. BMC Neurosci 2006;1:7-78
2. Zhang HY. One-compound-multipletargets strategy to combat Alzheimers disease. FEBS Lett 2005;579:5260-4
3. Richardson RL, Kim EM, Shepard RA, et al. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res 2002;954:1-10 (Pubitemid 35230002)
4. Rohn TT, Rissman RA, Head E, et al. Caspase activation in the Alzheimers disease brain: tortuous and torturous. Drug News Perspect 2002;15:549-57 (Pubitemid 36025540)
5. Cardinaux JR, Allaman I, Magistretti PJ. Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 2000;29:91-7 (Pubitemid 30031137)
6. Stefanis L, Park DS, Friedman WJ, et al. Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J Neurosci 1999;19:6235-47 (Pubitemid 29347424)
7. Brauner DJ, Muir JC, Sachs GA. Treating non dementia illnesses in patients with dementia. JAMA 2000;283(24):3230-5 (Pubitemid 30422041)
8. Slattum PW, Johnson MA. Caregiver burden in Alzheimers disease. Consult Pharm 2004;19(4):352-62
9. Mohamed S, Rosenheck R, Lyketsos K, et al. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry 2010;18(10):917-27
10. Parihar MS, Hemnani T. Alzheimers disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004;11(5):456-67 (Pubitemid 38869470)
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487-97 (Pubitemid 41127293)
12. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 2010;362(17):1553-5
13. Arlt S, Lindner R, Rosier A, et al. Adherence to medication in patients with dementia predictors and strategies for improvement. Drugs Aging 2008;25(12):1033-47
14. Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003;138(5):400-10 (Pubitemid 36262651)
15. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimers disease. Drugs 2000;60(5):1095-122
16. Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of Tacrine in drug toxicity and therapy of Alzheimers disease. Curr Drug Metab 2008;9(4):332-5 (Pubitemid 351836422)
17. Bleich S, Romer K, Wiltfang J. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003;18:S33-40 (Pubitemid 37150476)
18. Danysz W, Parsons CG. The NMDA receptor antagonist Memantine as a symptomatological and neuroprotective treatment for Alzheimers disease: preclinical evidence. Int J Geriatr Psychiatry 2003;18(1):S23-32 (Pubitemid 37150475)
19. Information on Aricept®, Pfizer. Available from: www.aricept.com/ [Last accessed 10 December 2010]
20. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69(5):459-69 (Pubitemid 47450281)
21. Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007;8(7):1011-23 (Pubitemid 351232608)
22. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimers disease: epidemiology and management. Drugs Aging 2001;18(11):853-62 (Pubitemid 34073130)
23. Information on Exelon®, Available from: http://www.pharma.us. novartis.com/product/pi/pdf/exelon.pdf [Last accessed 10 December 2010]
24. Seltzer B. Galantamine-er for the treatment of mild-to-moderate Alzheimers disease. Clin Interv Aging 2010;5:1-6
25. Information on Razadyne® ER, Ortho-McNeil Neurologics Inc. Available from: www.ortho-mcneilneurologics.com/products®razadyneer.html [Last accessed 07 April 2009]
26. Olin J, Schneider L. Galantamine for Alzheimers disease. Cochrane Database Syst Rev 2002;3:CD001747
27. Galasko D, Kershaw PR, Schneider L, et al. Galantamine maintains ability to perform activities of daily living in patients with Alzheimers disease. J Am Geriatr Soc 2004;52(7):1070-6 (Pubitemid 38869064)
28. Winblad B, Poritis N. Memantine in severe dementia: results of the M-best study (benefit and efficacy in severely demented patients during treatment with Memantine). Int J Geriatr Psychiatry 1999;14:135-46 (Pubitemid 29110331)
29. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimers disease. N Engl J Med 2003;348:1333-41
30. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving Donepezil. A randomized controlled trial. JAMA 2004;291:317-24 (Pubitemid 38101604)
31. Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimers disease. CNS Drugs 2009;23:293-307
32. Jones RW, Bayer A, Inglis F, et al. Safety and tolerability of once-daily versus twice-daily Memantine: a randomised, double-blind study in moderate to severe Alzheimers disease. Int J Geriatr Psychiatry 2007;22:258-62 (Pubitemid 46431716)
33. Alva G, Cummings JL. Relative tolerability of Alzheimers disease treatments. Psychiatry 2008;5(11):27-36
34. Abetz L, Rofail D, Mertzanis P, et al. Alzheimers disease treatment: assessing caregiver preferences for mode of treatment delivery. Adv Ther 2009;26(6):627-44
35. Herrmann N, Binder C, Dalziel W, et al. Persistence with cholinesterase inhibitor therapy for dementia an observational administrative health database study. Drugs Aging 2009;26(5):403-7
36. Muller MJ. Attitudes toward different formulations of psychotropic drugs: the view of patients and healthcare providers. Am J Drug Deliv 2006;4(1):33-41
37. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-309
38. Pushpangadan M, Feely M. Once a day is best: evidence or assumption? The relationship between compliance and dosage frequency in older people. Drugs Aging 1998;13(3):223-7 (Pubitemid 28461782)
39. Muramatsu RS, Litzinger MHJ, Fisher E, et al. Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am J Geriatr Pharmacother 2010;8:98-114
40. Comparison of 23 mg Donepezil sustained release (SR) to 10 mg Donepezil immediate release (IR) in patients with moderate to severe Alzheimers disease. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT00478205 [Last accessed 25 April 2010]
41. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of High-Dose (23 mg/d) versus Standard-dose (10 mg/d) Donepezil in moderate to severe Alzheimers disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32:1234-51
42. Open-Label Extension Study of 23 mg Donepezil SR in Patients with Moderate to Severe Alzheimers disease. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00566501 [Last accessed 3 December 2009]
43. Yan Y, Woo JS, Kang JH, et al. Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets. Biol Pharm Bull 2010;33(8):1364-70
44. Robinson DM, Plosker GL. Galantamine extended release. CNS Drugs 2006;20:673-81 (Pubitemid 44141494)
45. Zhao Q, Janssens L, Verhaeghe T, et al. Pharmacokinetics of extended-release and immediate-release formulations of Galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005;21:1547-54 (Pubitemid 41505021)
46. Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of Galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimers disease, in healthy subjects and patients. Curr Clin Pharmacol 2010;5:115-24
47. Brodaty H, Corey-Bloom J, Potocnik FCV, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimers disease. Dement Geriatr Cogn Disord 2005;20:120-32 (Pubitemid 41191627)
48. Dunbar F, Zhu Y, Brashear HR. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily Galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clin Ther 2006;28:365-72 (Pubitemid 43783439)
49. Scharre DW, Shiovitz T, Zhu Y, et al. One-week dose titration of extended release Galantamine in patients with Alzheimers disease. Alzheimers Dement 2008;4:30-7
50. Hing JP, Piotrovsky V, Kimko H, et al. Pharmacokinetic simulation for switching from Galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005;21:483-8
51. Wolff A, Beiski BZ, Sela Y. Oral devices and methods for controlled drug delivery. WO2004069076; 2004
52. Scholz OA, Wolff A, Schumacher A, et al. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov Today 2008;13:247-53
53. Pather SI, Rathbone MJ, Senel S. Current status and the future of buccal drug delivery systems. Expert Opin Drug Deliv 2008;5(5):531-42 (Pubitemid 351877432)
54. Giannola LI, Paderni C, De Caro V, et al. New perspectives in delivery of Galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies. Curr Pharm Des 2010;16:653-9
55. Whelpton R, Hurst P. Bioavailability of oral Physostigmine. New Eng J Med 1985;313:1293-4
56. Bolourchian N, Hadidi N, Foroutan SM, et al. Development and optimization of a sublingual tablet formulation for Physostigmine salicylate. Acta Pharm 2009;59:301-12
57. Information on Namenda XR®, Forest Pharmaceuticals. Available from: www.accessdata.fda.gov/drugsat fda®docs/label/2010/022525s000lbl.pdf [Last accessed June 2010]
58. Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimers disease. Expert Opin Pharmacother 2010;11:1765-71
59. Utsuki T, Uchimura N, Irikura M, et al. Preclinical investigation of the topical administration of Phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. J Pharmacol Exp Ther 2007;321(1):353-61 (Pubitemid 46456956)
60. Subedi RK, Oh SY, Chun1 MK, et al. Recent advances in transdermal drug delivery. Arch Pharm Res 2010;33(3):339-51
61. Chan ALF, Chien YW, Jin Lin S. Transdermal delivery of treatment for Alzheimers disease: development, clinical performance and future prospects. Drugs Aging 2008;25:761-75
62. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006;23:357-75 (Pubitemid 44050424)
63. Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69(4):S4-9 (Pubitemid 47205653)
64. Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res Technol 2008;14:249-60
65. Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm 2008;355:1-18
66. Motulsky A, Lafleur M, Couffin-Hoarau AC, et al. Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants. Biomaterials 2005;26:6242-53 (Pubitemid 40826993)
67. Packhaeuser CB, Schnieders J, Oster CG, et al. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445-55 (Pubitemid 39037247)
68. Cummings J, Lefevre G, Small G, et al. Pharmacokinetic rationale for the Rivastigmine patch. Neurology 2007;69(4):S10-13 (Pubitemid 47205654)
69. Emre M, Bernabei R, Blesa R, et al. Drug profile: transdermal Rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther 2010;16:246-53
70. Wentrup A, Oertel WH, Dodel R. Once-daily transdermal Rivastigmine in the treatment of Alzheimers disease. Drug Des Devel Ther 2008;2:245-54
71. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal Rivastigmine patch for the treatment of Alzheimers disease: a review. Int J Clin Pract 2009;63:799-805
72. Information on Exelon Patch®, Novartis Pharmaceuticals Corporation. Available from: http://www.exelonpatch.com/home.jsp [Last accessed 10 December 2010]
73. Lefevre G, Pommier F, Sedek G, et al. Pharmacokinetics and bioavailability of the novel Rivastigmine transdermal patch versus Rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008;48:246-52
74. Yang LPH, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimers type. CNS Drugs 2007;21:957-65 (Pubitemid 47557109)
75. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimers disease. Int J Clin Pract 2010;64:651-60
76. Sadowsky C, Davila Perez JA, Bouchard RW, et al. Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. CNS Neurosci Ther 2010;16:51-60
77. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimers disease - Rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67 (Pubitemid 46831690)
78. Grossberg G, Sadowsky C, Forstl H, et al. Safety and tolerability of the Rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009;23:158-64
79. Safety of switching from donepezil to rivastigmine patch in patients with probable Alzheimers disease. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00428389 [Last accessed 17 December 2008].
80. Sadowsky CH, Farlow MR, Meng X, et al. Safety and tolerability of Rivastigmine transdermal patch compared with Rivastigmine capsules in patients switched from Donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-93
81. Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral Rivastigmine in Alzheimers disease and Parkinsons disease dementia. Expert Opin Drug Saf 2010;9:167-76
82. Schmidt R, Alf C, Bancher C, et al. Transdermal Rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia. Neuropsychiatry 2009;23:58-63
83. Mumoli N, Carmignani G, Luschi R, et al. Hepatitis with cholestasis caused by Rivastigmine transdermal patch. Am J Gastroenterol 2009;104:2859-60
84. Effects of rivastigmine patch on activities of daily living and cognition in patients with severe dementia of the Alzheimers type (ACTION). ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT00948766?term=Rivastigmine+Patch&rank=3 [Last accessed 30 March 2010].
85. Comparative efficacy, safety, and tolerability of rivastigmine 10 and 15 cm2 patch in patients with Alzheimers disease (AD) showing cognitive decline. ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/show/ NCT00506415 [Last accessed 7 August 2009]
86. A 24 week open-label extension to study CENA713DUS44. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01054755 [Last accessed 1 February 2010]
87. Vintiloiu A, Lafleur M, Bastiat G, et al. In situ-forming oleogel implant for rivastigmine delivery. Pharm Res 2008;25(4):845-52 (Pubitemid 351661832)
88. Bastiat G, Plourde F, Motulsky A, et al. Tyrosine-based Rivastigmine-loaded organogels in the treatment of Alzheimers disease. Biomaterials 2010;31:6031-8
89. Wei-Ze L, Mei-Rong H, Jian-Ping Z, et al. Super-short solid silicon microneedles for transdermal drug delivery applications. Int J Pharm 2010;389:122-9
90. Benech H, Vincenti M, Fouchart F, et al. Development and in vivo assessment of a transdermal system for Physostigmine. Methods Find Exp Clin Pharmacol 1998;20:489-98 (Pubitemid 28442760)
91. Walter K, Muller M, Barkworth MF, et al. Pharmacokinetics of Physostigmine in man following a single application of a transdermal system. Br J Clin Pharmac 1995;39:59-63
92. Moller HJ, Hampel H, Hegerl U, et al. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a Physostigmine patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry 1999;32:99-106 (Pubitemid 29364443)
93. Coelho F, Birks J. Physostigmine for Alzheimers disease. Cochrane Database Syst Rev 2001;2:CD001499
94. Greig NH, Ruckle J, Comer P, et al. Anticholinesterase and pharmacokinetic profile of Phenserine in healthy elderly human subjects. Curr Alzheimer Res 2005;2:483-92 (Pubitemid 41277760)
95. Greig NH, Sambamurti K, Yu Q-S, et al. An overview of Phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimers disease. Curr Alzheimer Res 2005;2:281-90 (Pubitemid 40980186)
96. Telting-Diaz M, Lunte CE. Distribution of Tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. Pharm Res 1993;10:44-8 (Pubitemid 23020836)
97. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of Tacrine: I. Identification of a suitable delivery vehicle. Int J Pharm 1995;14:75-83 (Pubitemid 24377031)
98. Rawat S, Vengurlekar S, Rakesh B, et al. Transdermal delivery by iontophoresis. Indian J Pharm Sci 2008;70:5-10 (Pubitemid 351670561)
99. Jaskari T, Vuorio M, Kontturi K, et al. Controlled transdermal iontophoresis by ion-exchange fiber. J Control Release 2000;67:179-90 (Pubitemid 30303833)
100. Kankkunen T, Sulkava R, Vuorio M, et al. Transdermal iontophoresis of Tacrine in vivo. Pharm Res 2002;19:704-7 (Pubitemid 34553681)
101. Gore AV, Chien YW. The Nicotine transdermal system. Clin Dermatol 1998;16:599-615 (Pubitemid 29372796)
102. Levin ED, Conners CK, Silva D, et al. Transdermal Nicotine effects on attention. Psychopharmacology 1998;140:135-41 (Pubitemid 28538472)
103. Min S, Moon IW, Ko R, et al. Effects of transdermal Nicotine on attention and memory in healthy elderly non-smokers. Psychopharmacology 2002;159:83-8 (Pubitemid 34031255)
104. White HK, Levin ED. Four-week Nicotine skin patch treatment effects on cognitive performance in Alzheimers disease. Psychopharmacology 1999;143:158-65 (Pubitemid 29187640)
105. Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 2002;1:423-31
106. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000;283:1007-15 (Pubitemid 30112214)
107. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimers disease in women. Neurology 2000;54:295-301
108. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimers disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999;24:657-77 (Pubitemid 29277256)
109. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001;57:605-12 (Pubitemid 32782986)
110. Wharton W, Gleason CE, Lorenze KR, et al. Potential role of estrogen in the pathobiology and prevention of Alzheimers disease. Am J Transl Res 2009;1:131-47
111. Yue X, Lu M, Lancaster T, et al. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimers disease animal model. Proc Natl Acad Sci USA 2005;102:19198-203 (Pubitemid 43049589)
112. Craig MC, Murphy DGM. Alzheimers disease in women. Best Pract Res Clin Obstet Gynaecol 2009;23:53-61
113. Gleason CE, Carlsson CM, Johnson S, et al. Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Ann NY Acad Sci 2005;1052:93-115 (Pubitemid 41338961)
114. Chetkowski R, Meldrum D, Steingold K, et al. Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615-20
115. Information on Estraderm Patch®, Novartis Pharmaceuticals Corporation. Available from: www.pharma.us.novartis.com/info/products/name/ estraderm.jsp [Last accessed 25 February 2011]
116. Baker LD, Sambamurti K, Craft S, et al. 17beta-Estradiol reduces plasma Abeta40 for HRT-na?ve postmenopausal women with Alzheimer disease: a preliminary study. Am J Geriatr Psychiatry 2003;11:239-44
117. Hall KA, Keks NA, OConnor DW. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatr 2005;17:165-78 (Pubitemid 41073163)
118. Frey WH II. Neurologic agents for nasal administration to the brain. WO1991007947; 1991
119. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18 (Pubitemid 30410839)
120. Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insuline-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-96 (Pubitemid 38950662)
121. Sakane T, Akizuki M, Yoshida M, et al. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol 1991;43:449-51
122. Sakane T, Akizuki M, Yamashita S, et al. The transport of drugs to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 1991;39:2456-8
123. Kumar TA, David GFX, Sankaranarayanan A, et al. Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying. Proc Natl Acad Sci USA 1982;79:4185-9 (Pubitemid 12035102)
124. Wang Y, Aun R, Tse FL. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 1998;19:571-5 (Pubitemid 28548622)
125. Chow HS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 1999;88:754-8 (Pubitemid 29398540)
126. Chow HH, Anavy N, Villalobos A. Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci 2001;90:1729-35 (Pubitemid 33062593)
127. Liu XF, Fawcett JR, Throne RG, et al. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001;187:91-7 (Pubitemid 32618661)
128. Zhang QZ, Jiang XG, Wu CH. Distribution of nimodipine in brain following intranasal administration in rats. Acta Pharmacol Sin 2004;25:522-7
129. Westin U, Piras E, Jansson B, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005;24:565-73 (Pubitemid 40387270)
130. Wang D, Gao Y, Yun L. Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol 2006;57:97-104 (Pubitemid 41704922)
131. Merkus FW, Verhoef JC, Schipper NG, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998;29:13-38 (Pubitemid 28045041)
132. Lee VH, Yamamoto A. Penetration and enzymatic barriers of peptide and protein absorption. Adv Drug Deliv Rev 1990;4:171-207
133. Harris AS. Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin. J Pharm Sci 1986;75:1085-8 (Pubitemid 17216555)
134. Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm Res 2005;22:86-93 (Pubitemid 40558150)
135. Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99(4):1654-73
136. Costantino HR, Leonard AK, Brandt G, et al. Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci 2008;9(S6):1-3
137. Paskov DS. Galanthamine. The handbook of experimental pharmacology. Volume 79. Springer Verlag, Berlin Heidleberg; 1986
138. Leonard AK, Sileno AP, MacEvilly C, et al. Development of a novel high-concentration Galantamine formulation suitable for intranasal delivery. J Pharm Sci 2005;94:1736-46 (Pubitemid 41360868)
139. Leonard AK, Sileno AP, Brandt GC, et al. In vitro formulation optimization of intranasal Galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 2007;335:138-46
140. Yamahita M, Yamashita M, Tanaka J, et al. Vomiting induction by ipecac syrup in dogs and ferrets. J Toxicol Sci 1997;22:409-12 (Pubitemid 28030575)
141. Hasegawa M, Sasaki T, Sadakane K, et al. Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets, involvement of 5-hydroxyptamine receptors. Jpn J Pharmacol 2002;89:113-19 (Pubitemid 34752296)
142. Snape MF, Misra A, Murray TK, et al. A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors Tacrine, Donepezil and NXX-066. Neuropharmacology 1999;38:181-93 (Pubitemid 29073537)
143. Dahlin M, Bjork E. Nasal administration of a Physostigmine analogue (NXX-066) for Alzheimers disease to rats. Int J Pharm 2001;212:267-74 (Pubitemid 32119452)
144. Arumugam K, Subramanian GS, Mallayasamy SR, et al. A study of Rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008;58:287-97
145. Jogani VV, Shah PJ, Mishra P, et al. Nose-to-brain delivery of Tacrine. J Pharm Pharmacol 2007;59:1199-205 (Pubitemid 47359898)
146. Jogani VV, Shah PJ, Mishra P, et al. Intranasal mucoadhesive microemulsion of Tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 2008;22:116-24
147. Al-Ghananeem AM, Traboulsi AA, Dittert LW, et al. Targeted brain delivery of 17beta-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech 2002;3:40-7
148. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70:735-40
149. Nazem A, Mansoorib GA. Nanotechnology solutions for Alzheimers disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis 2008;13:199-223 (Pubitemid 352038525)
150. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005;78:585-94 (Pubitemid 41292080)
151. Kogan MJ, Bastus NG, Amigo R, et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett 2006;6(1):110-15 (Pubitemid 43166111)
152. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci 2006;7:65-74 (Pubitemid 41828932)
153. Saini P, Greenspan P, Lu DR. Adsorption of brain proteins on the surface of Poly (D,L-lactide-co-glycolide) (PLGA) Microspheres. Drug Deliv 1997;4(2):129-34 (Pubitemid 27276130)
154. Fournier E, Passirani C, Montero-Menei CN, et al. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003;24:3311-31 (Pubitemid 36577679)
155. Zhang P, Chen L, Gu W, et al. In vitro and in vivo evaluation of Donepezil-sustained release microparticles for the treatment of Alzheimers disease. Biomaterials 2007;28:1882-8 (Pubitemid 46123551)
156. Tan D, Zhao B, Moochhala S, Yang Y. Pharmacokinetic profile of a sustained-delivery system for Physostigmine in rats. Mater Sci Eng B 2006;132:155-8 (Pubitemid 44164568)
157. Wilson B, Samanta MK, Santhi K, et al. Poly(n-butylcyanoacrilate) nanoparticles coated with polysorbate 80 for the targeted delivery of Rivastigmine into the brain to treat Alzheimers disease. Brain Res 2008;1200:159-68
158. Craparo EF, Pitarresi G, Bondi ML, et al. A nanoparticulate drug-delivery system for Rivastigmine: physico-chemical and in vitro biological characterization. Macromol Biosci 2008;8:247-59
159. Quizilbash N, Birks J, Lopez Arrieta J, et al. Tacrine for Alzheimers disease. Cochrane Database of Syst Rev 2000;3:CD000202
160. Yang Q, Williams D, Owusu-Ababio G, et al. Controlled release tacrine delivery systems for the treatment of Alzheimers disease. Drug Deliv 2001;8:93-8 (Pubitemid 32494639)
161. Wilson B, Samanta MK, Santhi K, et al. Significant delivery of Tacrine into the brain using magnetic chitosan microparticles for treating Alzheimers disease. J Neurosci Methods 2009;177:427-33
162. Kumar V, Banker GS. Target-oriented drug delivery system. Marcel Dekker, New York; 1996
163. Wilson B, Samanta MK, Santhi K, et al. Targeted delivery of Tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008;70:75-84
164. Singh N, Seedat F, Pillay V, et al. Formulation and statistical optimization of novel double-incorporated PLA-PLGA microparticles within an alginate-pectinate platform for the delivery of Nicotine. J Microencapsul 2006;23(2):153-67 (Pubitemid 43840667)
165. Olanow CW. An introduction to the free radical hypothesis in Parkinsons disease. Ann Neurol 1992;32(1):S2-9
166. Christen Y. Oxidative stress and Alzheimers disease. Am J Clin Nutr 2000;71:621S-9S
167. Markesbery WR, Ehmann WD. Oxidative stress in Alzheimers disease. Philadelphia: Lippincott Williams and Wilkins; 1999
168. Kong S, Liochev S, Fridovich S. Aluminum (III) facilitates the oxidation of NADH by the superoxide anion. Free Radic Biol Med 1992;13(1):79-81
169. Liu G, Men P, Harris PLR, et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace imbalance. Neurosci Lett 2006;406:189-93 (Pubitemid 44311364)
170. Liu G, Men P, Perry G, Smith M. Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimers disease. J Nanoneurosci 2009;1(1):42-55
171. Cui Z, Lockman PR, Atwood CS, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimers and other CNS disease. Eur J Pharm Biopharm 2005;59:263-72 (Pubitemid 40127583)